Advanced Search

 

Study ID Status Title Patient Level Data
217744/086 Completed Single-blind, multicentre, phase IV clinical trial to assess and compare the immunogenicity and reactogenicity of GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™) and Aventis Pasteur’s DTPa-HBV-IPV-Hib vaccine (Hexavac™) given as a primary vaccination course at 2, 4 and 6 months of age. Study Listed on ClinicalStudyDataRequest.com
217744/088 Completed Phase IV, prospective study of the safety of GSK Biologicals' Pediarix administered to a cohort of infants in a US Health Maintenance Organization (HMO). (Post-Marketing PEDIARIX Safety Study)
217744/090 Completed A phase IV, open, multicentre study to assess the immunogenicity and reactogenicity of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix hexa() given as a primary vaccination course at 2, 4 and 6 months of age to pre-term infants. Study Listed on ClinicalStudyDataRequest.com
217744/093 Completed Phase IIIb, multicenter, open label, non controlled, study to assess immunogenicity and reactogenicity of GSK Infanrix hexa® (DTPa-HBV-IPV/Hib) and Infanrix Quinta® (DTPa-IPV/Hib) vaccines co-administered with Wyeth Prevenar® vaccine at different injection sites in healthy children
217744/094 Completed Study to assess and compare the immunogenicity and reactogenicity of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib vaccine (INFANRIX™ HEXA) and Aventis Pasteur MSD’s DTPa-HBV-IPV-Hib vaccine (HEXAVAC™) given at 3, 5 and 11-12 months of age Study Listed on ClinicalStudyDataRequest.com
217744/095 Completed Study to assess immunogenicity and reactogenicity of GSK Biologicals' DTPa-HBV-IPV/Hib vaccine when given as a booster dose to children previously primed at 2-4-6 months of age either with Aventis Pasteurs' DTPa-HBV-IPV-Hib vaccine or GSK Biologicals' DTPa-HBV-IPV/Hib vaccine in study DTPa-HBV-IPV-086 Study Listed on ClinicalStudyDataRequest.com
217744/097 Study to assess immunogenicity and reactogenicity of three doses of GSK Bio’s combined Hib-MenC vaccine co-admind with GSK Bio’s DTPa-HBV-IPV vaccine and of two doses of Baxters meningococcal C conjugate vaccine co-admind with GSK Bio’s DTPa-HBV-IPV/Hib vaccine Study Listed on ClinicalStudyDataRequest.com
217744/099 Completed A phase II, randomized, partially blinded clinical trial to evaluate the immunogenicity and reactogenicity of an investigational vaccine regimen of GSK Biologicals as compared to GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix™ hexa) and to the concomitant administration of GSK Biologicals’ DTPa-HBV-IPV (Infanrix™ penta) and Hib (Hiberix™) vaccines, when given as a primary vaccination to healthy infants at 2, 3 and 4 months of age Study Listed on ClinicalStudyDataRequest.com
217744/100 Completed Assess safety & reactogenicity of DTPa-IPV/Hib vaccine admnd at 3 & 4 mths & DTPa-HBV-IPV/Hib vaccine admnd at 5 mths, followed by DTPa-IPV/Hib vaccine at 18 mths in infants who received hepatitisB vaccine at birth & at one month of age Study Listed on ClinicalStudyDataRequest.com
218352/040 Completed Open immunization study to determine the reactogenicity and immunogenicity of Influsplit SSW® 1999/2000 (preservative-free) in persons as of 18 years of age.
218352/044 Completed Open immunization study to determine the reactogenicity and immunogenicity of Influsplit SSW® 2000/2001 in children aged from 6 months to < 6 years.
218352/047 Completed Open immunization study to determine the reactogenicity and immunogenicity of Influsplit SSW® 2001/2002 / Fluarix™ 2001/2002 in persons as of 18 years of age
218352/048 Completed Immunization study to determine the reactogenicity and immunogenicity of Influsplit SSW® 2001/2002 (preservative-free) in persons as of 18 years of age.
218352/049 Completed Immunization study to determine the reactogenicity and safety of Influsplit SSW® 2001/2002 (preservative-free) in persons as of 18 years of age
218352/051 Completed Open immunization study to determine the reactogenicity and immunogenicity of Influsplit SSW® 2002/2003 in persons as of 18 years of age
218352/052 Completed Open, multicentric, randomized, compared vaccination study to evaluate non-inferiority of influenza-vaccine Influsplit SSW®/Fluarix™ 2002/2003 versus the adjuvanted influenza-vaccines Fluad® 2002/2003 and Inflexal V® 2002/2003 concerning immunogenicity and reactogenicity in subjects aged over 60 years
218352/053 Completed Comparative vaccination study of the reactogenicity and immunogenicity of a thiomersal-free formulation of Influsplit SSW® 2002/2003 versus the standard formulation of Influsplit SSW® 2002/2003 in individuals over 18 years
218352/054 Completed Study to monitor the safety and reactogenicity of GlaxoSmithKline Biologicals’ influenza split vaccine FLUARIX™ administered according to the Prescribing Information in Korean subjects aged more than 6 months of age at the time of vaccination Study Listed on ClinicalStudyDataRequest.com
219550/012 Completed Open, multicentric, post marketing surveillance study of GlaxoSmithKline Biologicals’ Vi polysaccharide typhoid vaccine (TYPHERIX™) injected in healthy children and adults according to the Indian prescribing information.Typherix™: GlaxoSmithKline Biologicals’ Vi polysaccharide typhoid vaccine (Typh)
223030/059 Completed A Multicentre, Randomised, Double-Blind, Study of Idoxifene 40mg/dayversus Tamoxifene 20mg/day as First-Line Hormonal Therapy in Postmenopausal Women with Metastatic Breast Cancer
223030/150 Completed A combined report for protocols SB223030/015 and SB223030/016: a randomized, double-blind, placebo-controlled trial of the effect of idoxifene in the prevention of bone loss in early postmenopausal women and a randomized, double-blind, placebo-controlled trial of the effect of idoxifene in the p ...
223412/068 Completed An Eight-week, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety of talnetant in subjects with irritable bowel syndrome
227855/001 Completed Phase I study in elderly population aged over 65 years in order to evaluate reactogenicity and immunogenicity of GlaxoSmithKline Biologicals' experimental Influenza vaccine or a Whole virus vaccine. For both immunogenicity and safety evaluations, the commercial inactivated split vaccine Fluarix will be used as reference Study Listed on ClinicalStudyDataRequest.com
249553/004 Completed A Phase IIB Study to Assess the Efficacy of GSK 249553 as Adjuvant Therapy Given to MAGE-3-Positive Patients With Non-Small-Cell Lung Cancer in Stage IB (T2/N0) or II (T1/N1 or T2/N1 or T3/N0), Who Have Had Complete Surgical Resection
25000/233 Completed A Comparison of the Efficacy and Safety of Augmentin 875/125 mg po q 12 hrs and Augmentin 500/125 mg po q 8 hrs in the Treatment of Pyelonephritis and Complicated Urinary Tract Infections. A Double-Blind, Multi-Center, Comparative Study.

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.